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Abstract
The avian retroviruses reticuloendotheliosis virus strain A (REV-A) and spleen necrosis virus (SNV) are not naturally infectious in
human cells. However, REV-A-derived viral vectors efficiently infect human cells when they are pseudotyped with envelope proteins
displaying targeting ligands specific for human cell-surface receptors. Here we report that vectors containing the gag region of REV-A and
pol of SNV can be pseudotyped with the envelope protein of vesicular stomatitis virus (VSV) and the glycoproteins of different rabies virus
(RV) strains. Vectors pseudotyped with the envelope protein of the highly neurotropic RV strain CVS-N2c facilitated cell type-specific gene
delivery into mouse and human neurons, but did not infect other human cell types. Moreover, when such vector particles were injected into
the brain of newborn mice, only neuronal cells were infected in vivo. Cell-type-specific gene delivery into neurons may present quite specific
gene therapy approaches for many degenerative diseases of the brain.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Cell-type-specific gene delivery into neuronal cells will
be one of the most important prerequisites for in vivo gene
therapy of neurological disorders in humans (Costantini et
al., 2000; Sapolsky and Steinberg, 1999; Suhr and Gage,
1999). Although several viral vectors such as those derived
from herpes simplex viruses (HSV) or adenoassociated vi-
rus (AAV) show some preferential infection of neurons
when directly injected into the brain, an efficient and safe
gene delivery system entirely specific for neuronal cells has
not been developed (Berry et al., 2001; During and Leone,
1995; Jacobs et al., 1999).
To generate vectors specific for one cell type, experi-
ments have been initiated in several laboratories to endow
retroviral vectors with genetically modified envelope pro-
teins (Cosset and Russell, 1996; Dornburg, 1995, 1997;
Dornburg and Pomerantz, 2000), which mediate binding of
the virus to a specific receptor of the target cell (Hunter and
Swanstrom, 1990). In the past decade, our laboratory has
been developing cell-type-specific retroviral vectors derived
from spleen necrosis virus (SNV). SNV is a member of the
avian reticuloendotheliosis viruses (REV), which are not
infectious in human cells (Gautier et al., 2000). We have
demonstrated that SNV-derived retroviral vector particles,
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which display the antigen-binding site of an antibody (sin-
gle chain antibody, scA) against a human cell-surface pro-
tein made possible cell-type-specific gene delivery into hu-
man cells (Chu and Dornburg, 1995). The nature of the scA
played an important role in the efficiency of infection and a
highly efficient gene transfer into human cells could be
obtained in vitro (Chu and Dornburg, 1997; Chu et al.,
1994, 1995; Engelstadter et al., 2000; Jiang et al., 1998;
Jiang and Dornburg, 1999). In addition, first proof of prin-
ciple experiments showed that a cell-type-specific gene de-
livery could also be obtained in vivo (Jiang and Dornburg,
1999).
One of the major shortcomings of retroviral vectors de-
rived from C-type retroviruses, such as murine leukemia
virus (MLV) or REVs, is their inability to infect quiescent
cells such as neurons (Bukrinsky et al., 1993; Lewis and
Emerman, 1994; Schwedler et al., 1994). To bypass this
problem, we recently constructed SNV-derived vectors par-
ticles, which contain a nuclear localization sequence (NLS)
in the matrix (MA) protein. We showed that such vectors,
which displayed a scA specific for human hematopoietic
cells, assisted infection of quiescent human T lymphocytes
and macrophages in vitro (Parveen et al., 2000).
In the present study, we demonstrate that SNV-derived
vectors which display the envelope protein of rabies virus
(RVs) could transfer marker gene into neuronal cells in a
highly efficient manner. RVs are enveloped, nonsegmented,
negative-strand RNA viruses. RVs are highly neurotropic
and usually cause a fatal infection in all warm-blooded
species, with virus replication primarily occurring in neu-
rons. A single transmembrane envelope (G) protein is re-
sponsible for both the attachment to host cells receptor and
the fusion and release of the viral core into the cytoplasm.
Different RV strains differ in their preference for infecting
neuronal cells. Recently, two RV variants, termed CVS-N2c
and CVS-B2c, that differ genotypically and phenotypically,
were isolated from the mouse-adapted rabies virus strain
CVS-24 (Dietzschold et al., 2000; Morimoto et al., 1998,
1999, 2001). The RV strain CVS-N2c is highly neuroinva-
sive and neurotropic, whereas the RV strain CVS-B2c is
less neuroinvasive. Here we show that SNV-derived vectors
pseudotyped with the envelope of the RV strain CVS-N2c
facilitated cell-type-specific gene delivery into neuronal
cells in vitro and in vivo.
Results
Retroviral vectors
Previously, it has been reported that SNV virus particles
containing the gag proteins of the closely related reticulo-
endotheliosis virus strain A (REV-A) infect some mamma-
lian cells more efficiently than virus particles containing the
gag of SNV (Casella and Panganiban, 1993). Thus, we
constructed a series of new gag-pol gene expression vectors
containing gag of REV-A and pol of SNV (e.g., plasmid
pZP33, Fig. 1). We found that vectors containing REV-A
gag proteins infected human 293T cells approximately 10
times more efficiently than vectors containing gag of SNV
Fig. 1. Schematic of plasmid constructs. Plasmid DNA constructs to generate retroviral packaging cells. pZP33 is a plasmid that expresses reticuloendo-
theliosis virus gag-pol proteins from the cytomegalovirus (CMV) promoter followed by the adenovirus tripartite leader sequence (AVtl) for enhanced gene
expression (Martinez and Dornburg, 1995). Gag proteins have been derived from the reticuloendotheliosis virus strain A (REV-A) and the pol gene is from
SNV. To enable infection of quiescent cells, a nuclear translocalization sequence (NLS) has been introduced into MA of Gag, as described recently (Parveen
et al., 2000). PRD134 expressed the SNV wild-type envelope protein from the murine leukemia virus (MLV) U3 promoter. Plasmids pB2C and pN2C express
envelope proteins of the rabies virus strains B2C or N2C, respectively. pZP36 is an SNV-derived retroviral vector expressing bacterial -galactosidase gene.
The SNV U3 promoters in both LTRs have been replaced with the promoter of CMV.
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(A. Krupetsky and R. Dornburg, unpublished data). In ad-
dition, we introduced an NLS sequence into the REV-A,
matrix protein similar to that of the SNV MA, as described
recently (Parveen et al., 2000) (Fig. 1).
It has been reported that the SNV long terminal repeat
(LTR) promoter is weak in rodent cells (Embretson and
Temin, 1986). Therefore, to perform in vivo studies in mice,
we constructed a novel retroviral vector, which contains the
cytomegalovirus (CMV) promoter in both LTRs, replacing
the SNV LTR promoter (plasmid pZP36, Fig. 1). Using
pZP36, we were able to transduce the bacterial LacZ gene
into human 293T or dog D17 cells with titers similar to that
of vectors containing two SNV wild-type LTRs (data not
shown).
In vitro studies
To obtain an insight into whether vector particles
pseudotyped with the envelope proteins of rabies viruses are
infectious in human cells, transient transfection/infection
experiments were performed. To generate retroviral vector
particles, 293T cells were transfected with a plasmid ex-
pressing the reticuloendotheliosis virus core proteins
(pZP33), an SNV-derived plasmid expressing bacterial
-galactosidase gene (pZP36), and plasmids expressing the
VSV G protein, the rabies virus envelope proteins (strain
B2c or N2c, Fig. 1), or the SNV envelope protein. Forty-
eight hours after the transfection, viral supernatant was
harvested from transfected cell cultures. This supernatant
was used to transduce various dividing/growth-arrested tar-
get cells for the determination of infection, as described
previously (Mukhtar et al., 2000).
In agreement with our previous results (Chu et al., 1994;
Gautier et al., 2000), it was observed that retroviral particles
containing the envelope protein of wild-type (wt) SNV did
not infect human, mouse, or hamster cells (293T, NA, or
BSR cells, respectively). However, they infected dog D17
cells (Table 1). Retroviral particles pseudotyped with the
envelope protein of Vesicular stomatitis virus (VSV) in-
fected all cell lines tested with vector titers up to 104 colony
forming units per milliliter (CFU/ml) of tissue culture su-
pernatant medium (Table 1). Particles pseudotyped with the
rabies virus envelope protein of the virus strain B2C in-
fected human, hamster, and mouse cells with titers similar
to that obtained with particles pseudotyped with the enve-
lope protein of VSV (Indiana strain, Table 1). However,
some human cell lines such as 22-RvI and PC-3 cells (pros-
tate cancer cells) could not be infected (Table 1). Retroviral
vector particles pseudotyped with the envelope of the rabies
virus strain N2C only infected dividing and growth-arrested
mouse neuroblastoma cells (NA cells, Figs. 2A and B), but
no infection of the human or nonhuman cell lines could be
detected (Table 1). Similarly, N2C pseudotyped vectors did
not infect human SupT1 T cells, stromal, or Phillip skin
cells (data not shown). These in vitro experiments indicate
that retroviral vector particles can be pseudotyped with the
envelope proteins of rabies virus. Pseudotyping with the
envelope protein of the neurotropic virus N2c led to the
specific infection of mouse neuroblastoma cells in vitro.
Infectivity of N2C pseudotyped vectors was further
tested in differentiated mouse neurons prepared from NA
cells, as described previously (Palmer et al., 2001). These
cells were also infected with similar efficiency compared to
growth-arrested NA cells (Fig. 2C). To verify that the NA
cells had indeed differentiated into neurons, these cells were
stained with X-gal as well as with neuronal marker antibody
(NeuN) specific for a protein only expressed in mature
neuronal cells (Mullen et al., 1992). Approximately 99% of
all cells expressed this marker protein specific for mature
neurons (Fig. 2D).
To further test infectivity of REV vectors pseudotyped
with rabies virus envelope proteins, infectivity studies were
performed with differentiated human neurons derived from
Ntera-2 clonal human embryonal teratocarcinoma (NT2)
cells (Lee and Andrews, 1986). Differentiated human neu-
rons were obtained from NT2 precursor cell line as de-
scribed previously (Mukhtar et al., 2000), cultivated in
two-well chamber slides (Nalgene, Nunc) and infected with
200 l of viral stocks. Human neurons were also infected
with vectors containing VSV-G or rabies virus envelope
Table 1
Infectivity of retroviral vector particles pseudotyped with vsv or rabies virus envelope proteins
Envelope Target cells/vial titer (colony forming units)
22Rvl
dividing
PC-3
dividing
NIH 3T3
dividing
293T
dividing
BSR
dividing
NA
arrested
(growth)
NA
dividing
D17
dividing
VSV-G 2  103 1  103 1  103 5  103 1  104 1  103 nd nd
B2C 10 10 10 2  103 2.7  104 nd 2  103 nd
N2C 10 10 10 10 10 3.7  103 1.3  104 nd
SNV wt-Env 10 10 10 10 10 10 10 7  103
Note. 293T cells were transfected with the REV-A/SNV gag-pol expression vector pZP33, the retroviral vector pZP36 (Fig. 1), and plasmids expressing
the envelope indicated in the left column. After 48 h, supernatant containing virus was harvested for the transduction of various dividing and growth-arrested
cells. VSV-G, envelope of vesicular stomatitis virus; B2C and N2C envelopes of rabies virus strains B2C and N2C, respectively, were used. NA: rat
neuroblastoma cells; nd: not done.
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proteins. Up to 90% of the neuronal cells were infected and
no difference in the efficiency of infection was observed
between vector viruses displaying either RV or VSV enve-
lope proteins (data not shown). Fig. 2E shows human neu-
rons infected with vectors displaying the N2C envelope
proteins. Infection of human neuronal cells with REV-de-
rived vectors was found to be more efficient than that with
vectors derived from human immunodeficiency virus type I
(HIV-1) pseudotyped with the VSV-G protein (data not
shown). This finding is supported by previous reports that
HIV-1-derived vectors pseudotyped with the VSV envelope
infect neurons at relatively low levels (Bukrinsky et al.,
1993; Lewis and Emerman, 1994; Naldini et al., 1996a,
1996b; von Schwedler et al., 1994).
In another set of experiments, infectivity studies were
performed in primary mouse neurons. We isolated the brain
from 0-day-old mice, cut the hippocampal and dentate gyrus
areas into small pieces, and isolated neurons in tissue cul-
tures as described (Roy et al., 2000a, 2000b). Infectivity
experiments were performed with vectors displaying the
N2C envelope protein, when the cells were clearly differ-
entiated into mature neurons (approximately 6 weeks). We
found that mouse primary neuronal cells could also be
infected in vitro (Fig. 2F). After X-gal staining for the
presence of the bacterial LacZ protein, the plates were
stained with the NeuN antibody (Mullen et al., 1992). These
experiments confirmed that the infected cells (Fig. 2F) were
indeed mature neuronal cells (Fig. 2G).
In vivo studies
To test the infectivity of retroviral particles pseudotyped
with rabies virus envelope proteins in vivo, we injected viral
vector supernatant into the brain of newborn mice (strain
C57 BL/6 J-twi). For microinjection, retroviral vector par-
ticles were concentrated by ultracentrifugation (Burns et al.,
1993). Two microliters of concentrated virus solution (ap-
proximately 2  105 infectious virus particles) were in-
jected into the right lateral lobe or into the cerebellum. Two
months after the injection, the mice were sacrificed and the
whole brain was fixed, paraffin embedded, and sliced before
being subjected to immunostaining for LacZ expression.
We found that many of the cells around the injection sites
expressed the -galactosidase gene (Fig. 3B) and no differ-
ence in the efficiency of infection was observed between
viruses expressing rabies virus or VSV envelope proteins
(Table 2). Control mice were infected with tissue culture
medium harvested from cells expressing a retroviral vector
transducing the LacZ gene and the envelope protein of
SNV, without gag-pol proteins (Fig. 3B and Table 2) These
data indicate that SNV vector particles displaying the RV or
the VSV envelope are infectious in vivo.
To further investigate cell-type-specificity of vectors
pseudotyped with the CVS-N2C envelope, 0.5-m-thin his-
tological sections of the infected mice brain were prepared
(Naldini et al., 1996a, 1996b) and stained first with an
antibody against the bacterial -galactosidase and then with
NeuN (double staining). NeuN is a nuclei-specific antibody
and is not detectable in neurites (Mullen et al., 1992). In the
case of mice brains infected with vectors displaying the N2c
envelope, the expression of the LacZ gene was confined to
cells showing positive staining with the antibody against
neuronal cells. For example, hippocampal, cortical, as well
as some neurons in cerebellum region but none of the
Fig. 2. In vitro infection of neuronal cells with N2C-pseudotyped envelope.
All cells shown were infected with REV-derived vectors displaying the
rabies virus strain N2C envelope protein. The retroviral vectors transduced
the bacterial LacZ gene. Cells were stained for -galactosidase expression.
Blue cells indicate successful gene transfer. (A) Infectivity in dividing
mouse NA cells (infected with a 1:10 vector dilution); (B) infectivity in
growth-arrested NA cells (infected with a 1:10 vector dilution); (C) infec-
tivity in mouse mature neurons derived from NA cells; (D) the same cells
shown in C stained with an antibody specific for mature neurons (NeuN);
(E) infectivity in human neuronal cells derived from NT2 cells; (F) infec-
tivity in mouse neurons derived from primary mouse brain cells; (G) cells
shown in F were stained with an antibody specific for neuronal cells.
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Fig. 3. Mouse brains infected in vivo. Vector particles transducing the bacterial LacZ gene and pseudotyped with the envelope protein of the rabies virus strain
N2C were injected into the cerebellum of newborn C57 BL/6 J-twi mice at day 0. Two months after the injection, the mice were sacrificed and the brains
were removed, fixed with 4% paraformadehyde, paraffin embedded, and processed for respective antibody staining. A and A are the site of viral injection
in to the mice brain (arrows). A flux of macrophages is observable (arrow) at the site with phagocytic activity. B represents the same area with dual staining
using anti-LacZ and anti-NeuN antibodies. (negative control). B is a negative control micrograph for cerebellum with dual staining against LacZ and neurons.
C and C are cerebellum of mice infected with SNV vectors displaying rabies virus N2C envelope proteins with NeuN and LacZ staining.
surrounding nonneuronal cells expressed the bacterial -ga-
lactosidase protein (Fig. 3C; Figs. 4c, d, and f, respectively).
In the case of brains infected with vectors displaying the
CVS-B2c or VSV-G envelope, we found that -galactosi-
dase was expressed mainly in neurons showing preferential
neuronal infection with such vectors (Figs. 4h and i). How-
ever, in contrast to infectivity studies with N2c pseudotyped
vectors, we found regions in the cortex in which many
different cell types appeared to be infected with B2C
pseudotyped vectors (Fig. 4j). In another set of experiments,
thin sections of the brain were stained with an antibody
specific for astrocytes. We found that some astrocytes were
infected with vectors displaying the B2C envelope, but not
with vectors displaying the N2C envelope (data not shown).
These results coincide with results of our in vitro studies,
i.e., vectors pseudotyped with the B2c envelope infected not
only neurons, but also other cell types in vivo (Fig. 4j). Also
results obtained with VSV-G (Fig. 4h) pseudotyped vectors
were similar to that of B2C pseudotyped vectors. Vectors
displaying N2C envelope deliver gene specifically into neu-
rons compared with all other envelope pseudotypes de-
scribed in this study.
Discussion
Many degenerative diseases of the brain are caused by
single defective genes and, in these cases, lack of particular
protein expression manifest disease (Kalaria, 2001). Thus,
gene transfer into human neurons may become a powerful
tool to improve the health and well being of affected indi-
viduals (Costantini et al., 2000; Kalaria, 2001; Suhr and
Gage, 1999). However, the lack of an efficient and safe gene
delivery system specific for neurons constitutes one of the
major obstacles toward this goal.
In this study, we performed infectivity assays in neuronal
cells with REV-derived vectors pseudotyped with RV en-
velope proteins. SNV-derived vectors displaying the RV
envelope protein CVS-B2c, N2c infected human cells in
vitro with efficiency comparable to that of vectors
pseudotyped with the VSV-G protein. Vector virus titers
with virus stocks obtained in transient transfection/infection
experiments were comparable to vector virus titers of SNV
vectors displaying the SNV wild-type envelope in D17 cells
(Dornburg, 1995). Moreover, our data indicate that SNV
vectors pseudotyped with the envelope of highly neuro-
tropic RV strain, such as CVS-N2c, selectively infected
mouse and human neuronal cells in vitro.
Previously, we have reported that introduction of a NLS
sequence into the MA protein of SNV enabled the infection
of quiescent human T cells and macrophages in vitro (Par-
veen et al., 2000). Here, we describe that similar vectors
containing the complete gag region of REV-A and a NLS
sequence in MA, as described previously (Parveen et al.,
2000), also made possible infection of growth-arrested
mouse neuroblastoma cells as well as differentiated mouse
and human neurons in in vitro. However, no conclusions
can be drawn at this time on whether these vectors also
infect quiescent neurons in vivo, because the brain of new-
born mice is still not fully differentiated and the brain cells
also undergo some cell division. However, the present data
clearly indicate that vectors displaying the RV strain N2C
envelope infected only neurons in vivo, which was the
primary objective of this study.
In summary, we have demonstrated that reticuloendothe-
liosis virus derived vectors pseudotyped with RV envelope
proteins from highly neuroinvasive RV strains may have
great potential for targeted human gene therapy of neuro-
logical disorders. Such vectors not only facilitated efficient
infection of neuronal cells in vitro, but also sustained long-
term gene expression in vivo. However, to fully evaluate the
clinical therapeutic potential of this vector system, high-titer
packaging cell lines need to be constructed which express
various therapeutic genes. Such vectors could then be di-
rectly applied in animal model systems for various degen-
erative diseases and/or genetic defects of the brain.
Materials and methods
Plasmid constructs
Plasmid DNAs were constructed following standard DNA
cloning procedures. Retroviral core protein coding sequences
Table 2
In vivo infectivity of SNV vectors pseudotyped with VSV or rabies virus envelope proteins
SNV gag-pol Envelope proteins Site of injection No. mice injected/-Gal
pRD136-m7 (SNV gag) VSV-G Right lateral lobe 2/2
pZP33 (REV-A gag) VSV-G Right lateral lobe/cerebellum 6/6
pZP33 (REV-A gag) B2c Right lateral lobe/cerebellum 6/6
pZP33 (REV-A gag) N2c Right lateral lobe/cerebellum 7/7
Control (tissue culture medium) Right lateral lobe/cerebellum 2/0
Note. Newborn mice were infected with SNV-derived retroviral vectors displaying various envelope proteins and transduced with the -galactosidase gene.
Eight weeks after the injection of virus, the mice were sacrificed and the brains were analyzed for the expression of the marker gene. VSV-G, envelope protein
of vesicular stomatitis virus; B2C, envelope protein of the rabies virus strain B2C; N2C: envelope protein of the rabies virus strain N2C. Tissue culture
supernatant form nontransfected viral producing cells (293T) was used as a control.
79Z. Parveen et al. / Virology 314 (2003) 74–83
Fig. 4. Immunostaining of thin sections of mouse brains. Newborn mice were infected with REV-derived vectors pseudotyped with various envelope proteins.
Two months after infection, the brains were isolated and analyzed for cell-type-specific expression of the LacZ marker gene by double staining of thin sections
with an antibody specific for the expression of LacZ protein and neuron-specific antibody (NeuN). The NeuN antibody recognizes a protein which is located
or envelope genes were cloned into the universal eukaryotic
gene expression vectors pRD114 or pWS4 (Chu and Dorn-
burg, 1995). Plasmid pZP33 is similar to pRD136, which
expresses SNV gag-pol proteins (Martinez and Dornburg,
1995). However, pZP33 contains the gag coding sequences of
the REV-A. Using site-directed mutagenesis, a nuclear trans-
localization signal sequence has been introduced into MA
similar to plasmid construct pRD136-m7 (Parveen et al.,
2000). Gag-pol proteins are expressed from the CMV imme-
diate early promoter. Plasmid pMDG expresses the VSV en-
velope protein (Naldini et al., 1996a, 1996b), and plasmid
pRD134 expresses the SNV envelope protein (Martinez and
Dornburg, 1995). Plasmids pN2C and pB2C were constructed
using polymerase chain reaction (PCR) to amplify the enve-
lope coding sequences from cloned rabies virus cDNAs R-N2c
or R-B2c, respectively (Morimoto et al., 1998, 2001). The
primers used were: 5-CCTCTAGAAGATGGTTCCTCAG-
GCTC-3 and 5-TATAGGGCCCAAGCTTTCACAGTCT-
GATCTCACCTC-3. The PCR products were digested with
XbaI and HindIII and the resulting DNA fragments were
cloned into the universal gene expression vector pWS4 (Chu et
al., 1995) digested with XbaI and HindIII (Fig. 1).
The cell lines 293T (human embryonic kidney cells),
D17 (dog osteosarcoma cells), BSR (Chinese hamster kid-
ney), and primary cells obtained from mouse brains were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
(Gibco-BRL, USA) in the presence of 1% penicillin and 1%
streptomycin. NA (rat neuroblastoma cells) cells were
maintained in RPMI-1640 medium supplemented with 10%
fetal bovine serum in the presence of 1% penicillin and 1%
streptomycin. NT2 cells (Ntera2/D1 derived from a human
teratocarcinoma) were obtained from Stratagene (La Jolla,
CA). NT2 and NA cells were differentiated into mature
neurons by maintaining them in DMEM/F12 medium in the
presence of mitotic inhibitors and retinoic acid and by
plating them on poly-D-lysine and laminin-coated plates
following the protocol suggested by the supplier (Strat-
agene). Various cell types were growth-arrested using mit-
omycin as described previously (Bukrinsky et al., 1993;
Lewis and Emerman, 1994; Miyake et al., 1998; von Schw-
edler et al., 1994).
Generation of retroviral vector particles displaying rabies
virus envelope proteins. To generate retroviral particles that
display the envelope protein of a rabies virus, plasmids
expressing the retroviral core proteins (pZP33), the retrovi-
ral vector (pZP36), and plasmids expressing an envelope
protein (e.g., pN2C or pB2C) were cotransfected into hu-
man 293T cells. The transfections were performed using
Promega (Madison, WI) transfection kit according to man-
ufacturer-suggested protocols. Forty-eight hours after the
transfection, the supernatants were filtered through 0.45-m
Nalgene filters (Rochester, NY). The viral vector superna-
tants were used to transduce a variety of target cells. After
48 h, the infected target cells were stained for -galactosi-
dase expression as described previously (Mikawa et al.,
1991; Parveen et al., 2000). Concentrated virus stocks were
prepared as previously described (Burns et al., 1993).
Briefly, viral particles were harvested from transfected 293T
cells and passed through a 0.45 m filter (Nalgene). Thirty
milliliters of the virus solution was concentrated by ultra-
centrifugation in a Sorvall PC centrifuge at 25,000 rpm for
2 h. The viral pellet was resuspended in 100 l DMEM
medium. The titer of concentrated virus particles was de-
termined by infecting the 293T cells before injecting into
the mouse brain.
Viral injection into mouse brain
Zero-day-old mice (strain C57 BL/6J-wt/t) were posi-
tioned on a mini-light box with heads fixed and 2 l of viral
particles (2  105 CFU) was injected into the right and left
hemisphere or into the cerebellum, targeting the hippocam-
pal, cortical, or cerebellum, using a Hamilton syringe with
a 33-gauge needle (Hamilton, Reno, NV) at the rate of 0.2
l/min. The needle was left in the tissue for an extra 30 s to
completely remove the virus (Antel et al., 2000).
Histology
Eight weeks after the viral injections the animals were
anesthetized and sacrificed. The complete brains were re-
moved and washed in ice-cooled 1  PBS and then soaked
in 4% paraformaldehyde for 4 h followed by X-gal staining
or were paraffin embedded for histology and immunohis-
tostaining as described previously (Dhingra et al., 2000).
Immunostaining
Paraffin embedded brain tissues were sliced into 5-m
sections, deparaffinized in xylene, and then rehydrated in
cold 1  PBS before the standard H&E staining or immu-
nohistology, as described previously (Eberhardt et al., 2000;
Mullen et al., 1992; Naldini et al., 1996a, 1996b). For
-galactosidase detection, the tissues were incubated with a
mouse anti--galactosidase antibody (IgM, purchased from
Sigma, St. Louis, MO) followed by incubation with goat
anti-mouse IgM antibody termed Alexa fluor 546 (Molec-
ular Probes, Eugene, OR). As a negative control, tissue
sections were incubated with secondary antibody alone,
under similar conditions. Dual staining was performed for
the localization of LacZ gene expression and neurons with
around the nucleus. Thus, the neurites are not visible using this staining technique. a is standard H&E staining showing intact structural morphology. Panels
b–f are the hippocampal and cortical neuronal areas of the mice infected with N2C pseudotyped vectors. Panels g, h, i, and j are thin sections of the cortex
region of mice infected with VSV-G and B2C-pseudotyped vectors, respectively.
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the help of anti-LacZ antibody and mature neuronal marker
antibody, NeuN (IgG) (Chemicon International Temecula,
CA). Respective secondary antibodies, goat anti-mouse
(IgM, Alexa Fluor 546) and rabbit anti-mouse IgG (Alexa
Fluor 647), were used to detect the expression of each
protein individually in each cell.
Isolation of neurons from mouse brain cells
Zero-day-old mice brain were isolated as described
above (under Histology) and the hippocampal and cerebel-
lum tissues were separated from brain and cut into small
pieces, rinsed twice with ice-cold phosphate-buffered saline
(PBS), and incubated at 37°C for 15 min in PBS containing
0.025% trypsin, 10 g/ml DNase and papain, and 3 mM
MgCl2. After adjusting the solution to 15% FBS, the cell
suspension was centrifuged for 10 min at 200 g and resus-
pended in DMEM/F12 with 20 nM FGF-2 (Sigma) and 10%
nonactive FBS (Parveen et al., 2000). After 4 days in cul-
ture, the cells were transferred to poly-D-lysine and laminin-
coated plates and cultivated as described earlier (under cell
lines and culture), until they matured into neurons.
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